Bonus BioGroup Ltd.
Tel Aviv Stock Exchange BONS.TA
Bonus BioGroup Ltd. Price to Sales Ratio (P/S) on January 14, 2025
-
Bonus BioGroup Ltd. 52-week high Price to Sales Ratio (P/S) is NA on January 14, 2025, which is NA below the current Price to Sales Ratio (P/S).
-
Bonus BioGroup Ltd. 52-week low Price to Sales Ratio (P/S) is NA on January 14, 2025, which is NA below the current Price to Sales Ratio (P/S).
-
Bonus BioGroup Ltd. average Price to Sales Ratio (P/S) for the last 52 weeks is NA.
| Date | Price to Sales Ratio (P/S) | Price to Book Ratio (P/B) | Dividend Yield | Free Cash Flow Yield |
|---|
| CEO | Dr. Shai Meretzki Ph.D. |
| IPO Date | Aug. 12, 2002 |
| Location | Israel |
| Headquarters | Matam Advanced Technology Park |
| Employees | 58 |
| Sector | Health Care |
| Industries | |
Bonus BioGroup Ltd., a clinical-stage biotechnology company, develops products based on tissue engineering and cell therapy. The company's products include BonoFill for bone tissue regeneration in maxillofacial and orthopedic indications; and MesenCure for the treatment of COVID patients suffering from pneumonia and ARDS, as well as other life-threatening acute inflammatory diseases. Its products in pipeline comprise bone augmentation in osteoporosis patients; novel nano-materials for drug delivery; vascularized bone grafts; and soft tissue grafts. The company was formerly known as Oceana Advanced Industries Ltd. Bonus BioGroup Ltd. was founded in 1981 and is based in Haifa, Israel.
Past 5 years
StockViz Staff
January 15, 2025
Any question? Send us an email